De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Proteome Sciences Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Proteome Sciences.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Life Sciences winstgroei	25.9%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely

May 10

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Proteome Sciences onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

AIM:PRM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (GBP Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	4	-4	-2	-2	N/A
3/31/2024	5	-3	-1	-1	N/A
12/31/2023	5	-2	-1	0	N/A
9/30/2023	6	-1	1	1	N/A
6/30/2023	8	1	2	2	N/A
3/31/2023	8	1	2	2	N/A
12/31/2022	8	1	2	2	N/A
9/30/2022	7	1	2	2	N/A
6/30/2022	6	1	2	2	N/A
3/31/2022	6	0	1	1	N/A
12/31/2021	5	0	1	1	N/A
9/30/2021	5	0	1	1	N/A
6/30/2021	5	0	1	1	N/A
3/31/2021	5	0	1	1	N/A
12/31/2020	5	0	2	2	N/A
9/30/2020	5	0	1	1	N/A
6/30/2020	5	0	1	1	N/A
3/31/2020	5	0	0	0	N/A
12/31/2019	5	0	0	0	N/A
9/30/2019	4	0	0	0	N/A
6/30/2019	3	0	0	0	N/A
3/31/2019	3	-1	0	0	N/A
12/31/2018	3	-1	-1	-1	N/A
9/30/2018	3	-2	0	0	N/A
6/30/2018	3	-2	0	0	N/A
3/31/2018	3	-2	N/A	-1	N/A
12/31/2017	3	-2	N/A	-2	N/A
9/30/2017	3	-2	N/A	-2	N/A
6/30/2017	3	-2	N/A	-3	N/A
3/31/2017	3	-2	N/A	-2	N/A
12/31/2016	3	-2	N/A	-2	N/A
9/30/2016	2	-3	N/A	-2	N/A
6/30/2016	2	-3	N/A	-2	N/A
3/31/2016	2	-3	N/A	-2	N/A
12/31/2015	2	-3	N/A	-2	N/A
9/30/2015	2	-3	N/A	-3	N/A
6/30/2015	2	-3	N/A	-3	N/A
3/31/2015	2	-3	N/A	-3	N/A
12/31/2014	2	-4	N/A	-3	N/A
9/30/2014	2	-3	N/A	-3	N/A
6/30/2014	2	-3	N/A	-3	N/A
3/31/2014	2	-3	N/A	-3	N/A
12/31/2013	2	-3	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if PRM's forecast earnings growth is above the savings rate (1.9%).

Winst versus markt: Insufficient data to determine if PRM's earnings are forecast to grow faster than the UK market

Hoge groeiwinsten: Insufficient data to determine if PRM's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if PRM's revenue is forecast to grow faster than the UK market.

Hoge groei-inkomsten: Insufficient data to determine if PRM's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if PRM's Return on Equity is forecast to be high in 3 years time

Proteome Sciences Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Proteome Sciences plc Provides Earnings Guidance for the Financial Year Ended 31 December 2021

Recent updates

New major risk - Market cap size

New major risk - Revenue and earnings growth

Proteome Sciences plc Announces Step Down of Dr Mariola Soehngen as Chief Executive Officer at the End of January 2025

Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely

New major risk - Share price stability

Full year 2023 earnings released: UK£0.008 loss per share (vs UK£0.004 profit in FY 2022)

Proteome Sciences plc, Annual General Meeting, May 16, 2024

New minor risk - Financial data availability

New major risk - Share price stability

Here's Why We Think Proteome Sciences (LON:PRM) Is Well Worth Watching

Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro™ Isobaric Labelling Reagents

First half 2023 earnings released: UK£0.002 loss per share (vs UK£0 in 1H 2022)

Now 43% undervalued

Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors

Full year 2022 earnings released: EPS: UK£0.004 (vs UK£0 in FY 2021)

Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors

Less than half of directors are independent

Do Proteome Sciences' (LON:PRM) Earnings Warrant Your Attention?

Proteome Sciences plc Appoints Abdel Ghani Omari as the Company's New Chief Financial Officer

First half 2022 earnings released

Proteome Sciences plc Completes Milestone Towards Launch of single Cell Proteomics Services

Less than half of directors are independent

Full year 2021 earnings released: EPS: UK£0 (vs UK£0.001 in FY 2020)

Proteome Sciences plc, Annual General Meeting, May 16, 2022

Now 25% undervalued after recent price drop

Proteome Sciences plc to Report Fiscal Year 2021 Results on Mar 31, 2022

Now 21% undervalued after recent price drop

Now 23% undervalued after recent price drop

Proteome Sciences plc Provides Earnings Guidance for the Financial Year Ended 31 December 2021

Calculating The Fair Value Of Proteome Sciences plc (LON:PRM)

First half 2021 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2020)

Does Proteome Sciences (LON:PRM) Deserve A Spot On Your Watchlist?

Some Confidence Is Lacking In Proteome Sciences plc's (LON:PRM) P/E

Full year 2020 earnings released: EPS UK£0.001 (vs UK£0.001 in FY 2019)

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven